Valuation: Candel Therapeutics, Inc.

Market Cap 66Cr 59Cr 55Cr 50Cr 93Cr 6.32TCr 94Cr 654.04Cr 260.92Cr 3.31TCr 248.97Cr 243.67Cr 10TCr P/E 2026 *
-6.12x
P/E 2027 * -7.42x
Enterprise Value 66Cr 59Cr 55Cr 50Cr 93Cr 6.32TCr 94Cr 654.04Cr 260.92Cr 3.31TCr 248.97Cr 243.67Cr 10TCr EV / Sales 2026 *
-
EV / Sales 2027 * 15.8x
Free-Float
85.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Candel Therapeutics, Inc.

1 day-0.23%
1 week+3.35%
Current month-17.15%
1 month-22.70%
3 months-10.64%
6 months+39.52%
Current year+53.10%
1 week 7.7
Extreme 7.7
8.93
1 month 7.7
Extreme 7.7
11.24
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.6
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 80 01/09/2017
Director/Board Member 66 01/09/2020
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

380 0.0005%
30/09/26 Free

Chairman

2,189 0.0029%
30/09/26 Free

Director

1,325 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%+3.35%+54.46%+861.32% 66Cr
+0.34%-3.03%+37.45%+61.06% 6.41TCr
+0.98%+2.26%+12.91%+82.98% 5.55TCr
+1.75%+2.76%+12.38%+103.69% 5.3TCr
-1.43%-0.57%+26.10%+52.86% 4.6TCr
-0.48%-3.86%+17.27%+117.99% 4.25TCr
+0.82%-2.06%+227.09%+922.41% 4.04TCr
-0.26%-4.20%+10.86%+45.18% 3.23TCr
-2.07%+44.58%+102.84%+88.74% 3.45TCr
-2.72%-8.79%+22.58%-5.63% 2.42TCr
Average -0.36%+3.80%+52.39%+233.06% 3.93TCr
Weighted average by Cap. -0.11%+3.13%+49.27%+162.06%

Financials

2026 *2027 *
Net sales - 4.19Cr 3.75Cr 3.46Cr 3.13Cr 5.86Cr 399.16Cr 5.96Cr 41Cr 16Cr 208.9Cr 16Cr 15Cr 661.63Cr
Net income -10Cr -9.1Cr -8.39Cr -7.59Cr -14Cr -967.07Cr -14Cr -100.12Cr -40Cr -506.12Cr -38Cr -37Cr -1.6TCr -9.23Cr -8.27Cr -7.63Cr -6.9Cr -13Cr -879.22Cr -13Cr -91Cr -36Cr -460.14Cr -35Cr -34Cr -1.46TCr
Net Debt - -
Projected Income Statement - Annual - Candel Therapeutics, Inc.
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
30/26/30 $8.650 -0.23% 7,40,796
28/26/28 $8.670 +5.09% 6,63,859
27/26/27 $8.250 +5.91% 9,28,461
26/26/26 $7.790 -2.99% 8,49,302
23/26/23 $8.030 -4.18% 11,84,816
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Candel Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.635USD
Average target price
22.11USD
Spread / Average Target
+156.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Candel Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CADL Stock